Hostname: page-component-cb9f654ff-c75p9 Total loading time: 0 Render date: 2025-08-26T05:40:08.739Z Has data issue: false hasContentIssue false
  • English
  • Français

Exploring hypoxic biology to improve radiotherapy outcomes

Part of: Advancements in the radiobiology of low and high-LET radiation

Published online by Cambridge University Press:  27 April 2022

Chun Li ,
Lucy Wiseman ,
Ene Okoh ,
Michael Lind ,
Rajarshi Roy Open the ORCID record for Rajarshi Roy [Opens in a new window] ,
Andrew W. Beavis Open the ORCID record for Andrew W. Beavis [Opens in a new window]  and
Isabel M. Pires Open the ORCID record for Isabel M. Pires [Opens in a new window]
Chun Li
Affiliation:
Hypoxia and Tumour Microenvironment Lab, Department of Biomedical Sciences, Faculty of Health Sciences, University of Hull, Hull, UK
Lucy Wiseman
Affiliation:
Hypoxia and Tumour Microenvironment Lab, Department of Biomedical Sciences, Faculty of Health Sciences, University of Hull, Hull, UK
Ene Okoh
Affiliation:
Hypoxia and Tumour Microenvironment Lab, Department of Biomedical Sciences, Faculty of Health Sciences, University of Hull, Hull, UK
Michael Lind
Affiliation:
Queen's Centre for Oncology and Haematology, Castle Hill Hospital, Castle Rd, Cottingham HU16 5JQ, UK Faculty of Health Sciences, University of Hull, Cottingham Road, Hull, HU16 7RX, UK
Rajarshi Roy
Affiliation:
Queen's Centre for Oncology and Haematology, Castle Hill Hospital, Castle Rd, Cottingham HU16 5JQ, UK
Andrew W. Beavis
Affiliation:
Faculty of Health Sciences, University of Hull, Cottingham Road, Hull, HU16 7RX, UK Department of Medical Physics, Queen's Centre for Oncology, Hull University Teaching Hospitals NHS Trust, Cottingham, HU16 5JQ, UK Faculty of Health and Well Being, Sheffield-Hallam University, Collegiate Crescent, Sheffield, S10 2BP, UK
Isabel M. Pires*
Affiliation:
Hypoxia and Tumour Microenvironment Lab, Department of Biomedical Sciences, Faculty of Health Sciences, University of Hull, Hull, UK
*
Author for correspondence: Isabel M. Pires, E-mail: i.pires@hull.ac.uk
Get access Rights & Permissions [Opens in a new window]

Abstract

Ionising radiotherapy is a well-established, effective cancer treatment modality, whose efficacy has improved with the application of newer technological modalities. However, patient outcomes are governed and potentially limited by aspects of tumour biology that are associated with radioresistance. Patients also still endure treatment-associated toxicities owed to the action of ionising radiation in normoxic tissue adjacent to the tumour mass. Tumour hypoxia is recognised as a key component of the tumour microenvironment and is well established as leading to therapy resistance and poor prognosis. In this review, we outline the current understanding of hypoxia-mediated radiotherapy resistance, before exploring targeting tumour hypoxia for radiotherapy sensitisation to improve treatment outcomes and increase the therapeutic window. This includes increasing oxygen availability in solid tumours, the use of hypoxia-activated prodrugs, targeting of hypoxia-regulated or associated signalling pathways, as well as the use of high-LET radiotherapy modalities. Ultimately, targeting hypoxic radiobiology combined with precise radiotherapy delivery modalities and modelling should be associated with improvement to patient outcomes.

Keywords

DNA damage responseHAPsHIFhypoxiaradioresistanceradiotherapytargeted therapy

Information

Type
Review
Information
Expert Reviews in Molecular Medicine , Volume 24 , 2022 , e21
Copyright
Copyright © The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Reisz, JA et al. (2014) Effects of ionizing radiation on biological molecules – mechanisms of damage and emerging methods of detection. Antioxidants & Redox Signaling 21, 260–292.CrossRefGoogle ScholarPubMed
Bahadoer, RR et al. (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. The Lancet Oncology 22, 29–42.CrossRefGoogle ScholarPubMed
Nishimura, H et al. (2012) Radiotherapy for stage I or II hypopharyngeal carcinoma. Journal of Radiation Research 53, 892–899.CrossRefGoogle ScholarPubMed
Anderson, G et al. (2021) An updated review on head and neck cancer treatment with radiation therapy. Cancers 13, 4912.CrossRefGoogle ScholarPubMed
Theelen, W et al. (2021) Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. The Lancet. Respiratory Medicine 9, 467–475.CrossRefGoogle ScholarPubMed
Gray, LH et al. (1959) The influence of oxygen and peroxides on the response of mammalian cells and tissues to ionizing radiations. Prog Nucl Energy 6 Biological Sciences 2, 69–81.Google ScholarPubMed
Goodhead, DT (1999) Mechanisms for the biological effectiveness of high-LET radiations. Journal of Radiation Research 40(suppl), 1–13.CrossRefGoogle ScholarPubMed
Brizel, DM et al. (1996) Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. Cancer Research 56, 5347–5350.Google ScholarPubMed
Nordsmark, M et al. (2005) Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiotherapy & Oncology 77, 18–24.CrossRefGoogle ScholarPubMed
Nordsmark, M et al. (2006) The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study. Radiotherapy & Oncology 80, 123–131.CrossRefGoogle ScholarPubMed
Hammond, EM et al. (2014) The meaning, measurement and modification of hypoxia in the laboratory and the clinic. Clinical Oncology 26, 277–288.CrossRefGoogle ScholarPubMed
Bassler, N et al. (2014) LET-painting increases tumour control probability in hypoxic tumours. Acta Oncologica 53, 25–32.CrossRefGoogle ScholarPubMed
Tinganelli, W et al. (2015) Kill-painting of hypoxic tumours in charged particle therapy. Scientific Reports 5, 17016.CrossRefGoogle ScholarPubMed
Hill, RP et al. (2015) Hypoxia and predicting radiation response. Seminars in Radiation Oncology 25, 260–272.CrossRefGoogle ScholarPubMed
Vaupel, P and Mayer, A (2017) Tumor oxygenation status: facts and fallacies. Advances in Experimental Medicine and Biology 977, 91–99.CrossRefGoogle ScholarPubMed
Saxena, K and Jolly, MK (2019) Acute vs. chronic vs. cyclic hypoxia: their differential dynamics, molecular mechanisms, and effects on tumor progression. Biomolecules 9, 339.CrossRefGoogle ScholarPubMed
Bader, SB, Dewhirst, MW and Hammond, EM (2020) Cyclic hypoxia: an update on its characteristics, methods to measure it and biological implications in cancer. Cancers 13, 23.CrossRefGoogle ScholarPubMed
Majmundar, AJ, Wong, WJ and Simon, MC (2010) Hypoxia-inducible factors and the response to hypoxic stress. Molecular Cell 40, 294–309.CrossRefGoogle ScholarPubMed
Kabakov, AE and Yakimova, AO (2021) Hypoxia-induced cancer cell responses driving radioresistance of hypoxic tumors: approaches to targeting and radiosensitizing. Cancers 13, 1102.CrossRefGoogle ScholarPubMed
Fong, GH and Takeda, K (2008) Role and regulation of prolyl hydroxylase domain proteins. Cell Death & Differentiation 15, 635–641.CrossRefGoogle ScholarPubMed
Kubaichuk, K and Kietzmann, T (2019) Involvement of E3 ligases and deubiquitinases in the control of HIF-α subunit abundance. Cells 8, 598.CrossRefGoogle ScholarPubMed
Dames, SA et al. (2002) Structural basis for Hif-1 alpha/CBP recognition in the cellular hypoxic response. Proceedings of the National Academy of Sciences of the USA 99, 5271–5276.CrossRefGoogle ScholarPubMed
Masoud, GN and Li, W (2015) HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharmaceutica Sinica B 5, 378–389.CrossRefGoogle ScholarPubMed
Wang, H et al. (2019) Hypoxic radioresistance: can ROS be the key to overcome it? Cancers 11, 112.Google Scholar
Lomax, ME, Folkes, LK and O'Neill, P (2013) Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. Clinical Oncology 25, 578–585.CrossRefGoogle Scholar
Brown, JM (2020) Radiation damage to tumor vasculature initiates a program that promotes tumor recurrences. International Journal of Radiation Oncology Biology Physics 108, 734–744.CrossRefGoogle ScholarPubMed
Aebersold, DM et al. (2001) Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Research 61, 2911–2916.Google ScholarPubMed
Koukourakis, MI et al. (2002) Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. International Journal of Radiation Oncology Biology Physics 53, 1192–1202.CrossRefGoogle Scholar
Dewhirst, MW et al. (2007) Exploring the role of HIF-1 in early angiogenesis and response to radiotherapy. Radiotherapy & Oncology 83, 249–255.CrossRefGoogle Scholar
Chan, N et al. (2008) Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Research 68, 605–614.CrossRefGoogle ScholarPubMed
Hassan Venkatesh, G et al. (2020) Hypoxia increases mutational load of breast cancer cells through frameshift mutations. Oncoimmunology 9, 1750750.CrossRefGoogle ScholarPubMed
Lu, Y et al. (2014) Silencing of the DNA mismatch repair gene MLH1 induced by hypoxic stress in a pathway dependent on the histone demethylase LSD1. Cell Reports 8, 501–513.CrossRefGoogle Scholar
Pires, IM et al. (2010) Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. Cancer Research 70, 925–935.CrossRefGoogle ScholarPubMed
Olcina, MM et al. (2013) Replication stress and chromatin context link ATM activation to a role in DNA replication. Molecular Cell 52, 758–766.CrossRefGoogle ScholarPubMed
Foskolou, IP et al. (2017) Ribonucleotide reductase requires subunit switching in hypoxia to maintain DNA replication. Molecular Cell 66, 206–220. e209.CrossRefGoogle ScholarPubMed
Bennett, MH et al. (2016) Hyperbaric oxygen therapy for late radiation tissue injury. The Cochrane Database of Systematic Reviews 4, Cd005005.Google ScholarPubMed
Overgaard, J (2011) Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck – a systematic review and meta-analysis. Radiotherapy & Oncology 100, 22–32.CrossRefGoogle ScholarPubMed
Kunugita, N et al. (2001) Radiotherapy after hyperbaric oxygenation improves radioresponse in experimental tumor models. Cancer Letters 164, 149–154.CrossRefGoogle ScholarPubMed
Hoskin, PJ et al. (2010) Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. Journal of Clinical Oncology 28, 4912–4918.CrossRefGoogle ScholarPubMed
Tharmalingham, H and Hoskin, P (2019) Clinical trials targeting hypoxia. The British Journal of Radiology 92, 20170966.Google ScholarPubMed
Janssens, GO et al. (2012) Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. Journal of Clinical Oncology 30, 1777–1783.CrossRefGoogle ScholarPubMed
Gainer, JL et al. (2017) Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme. Journal of Neurosurgery 126, 460–466.CrossRefGoogle ScholarPubMed
Sheehan, J et al. (2010) Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide. Journal of Neurosurgery 113, 234–239.CrossRefGoogle ScholarPubMed
Murayama, C et al. (2012) Liposome-encapsulated hemoglobin ameliorates tumor hypoxia and enhances radiation therapy to suppress tumor growth in mice. Artificial Organs 36, 170–177.CrossRefGoogle ScholarPubMed
Le Moan, N et al. (2017) Abstract 4686: Omx a hypoxia modulator reverses the immunosuppressive glioblastoma microenvironment by stimulating T cell infiltration and activation that results in increased number of long-term survivors. Cancer Research 77, 4686.Google Scholar
Johnson, JLH (2017) Oxygen carriers: are they enough for cellular support? In Lapchak, PA and Zhang, JH (eds), Neuroprotective Therapy for Stroke and Ischemic Disease. Cham: Springer International Publishing, pp. 621–640.CrossRefGoogle Scholar
NuvOx, LLC (2019) NVX-108 combined with radiation & TMZ, and during maintenance phase for newly-diagnosed glioblastoma multiform. Available at https://clinicaltrials.gov/ct2/show/NCT03862430.Google Scholar
Farah, C, Michel, LYM and Balligand, JL (2018) Nitric oxide signalling in cardiovascular health and disease. Nature Reviews Cardiology 15, 292–316.CrossRefGoogle ScholarPubMed
Scicinski, J et al. (2015) No to cancer: the complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001. Redox Biology 6, 1–8.CrossRefGoogle ScholarPubMed
Wardman, P et al. (2007) Radiosensitization by nitric oxide at low radiation doses. Radiation Research 167, 475–484.CrossRefGoogle ScholarPubMed
Ashton, TM et al. (2016) The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. Nature Communications 7, 12308.CrossRefGoogle ScholarPubMed
Skwarski, M et al. (2021) Mitochondrial inhibitor atovaquone increases tumor oxygenation and inhibits hypoxic gene expression in patients with non-small cell lung cancer. Clinical Cancer Research 27, 2459–2469.CrossRefGoogle ScholarPubMed
Benej, M et al. (2018) Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism. Proceedings of the National Academy of Sciences of the USA 115, 10756–10761.CrossRefGoogle ScholarPubMed
Benej, M et al. (2021) Pharmacological regulation of tumor hypoxia in model murine tumors and spontaneous canine tumors. Cancers 13, 1696.CrossRefGoogle ScholarPubMed
Coates, JT, Skwarski, M and Higgins, GS (2019) Targeting tumour hypoxia: shifting focus from oxygen supply to demand. The British Journal of Radiology 92, 20170843.Google ScholarPubMed
Overgaard, J et al. (1989) Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix. International Journal of Radiation Oncology, Biology, Physics 16, 1069–1072.CrossRefGoogle ScholarPubMed
Panduro, J et al. (1983) Misonidazole combined with radiotherapy in the treatment of inoperable squamous cell carcinoma of the lung a double-blind randomized trial. Cancer 52, 20–24.3.0.CO;2-V>CrossRefGoogle Scholar
Thomson, D et al. (2014) NIMRAD – a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer. Clinical Oncology 26, 344–347.CrossRefGoogle ScholarPubMed
Guidelines, CFCP and Cancer (2020) Treatment with the hypoxic radiosensitizer Nimorazole in squamous cell carcinoma of the head and neck. January 14th 2021 (Center for Clinical Practice Guidelines|Cancer).Google Scholar
Mistry, IN et al. (2017) Clinical advances of hypoxia-activated prodrugs in combination with radiation therapy. International Journal of Radiation Oncology, Biology, Physics 98, 1183–1196.CrossRefGoogle ScholarPubMed
Zeng, Y et al. (2018) Hypoxia-activated prodrugs and redox-responsive nanocarriers. International Journal of Nanomedicine 13, 6551–6574.CrossRefGoogle ScholarPubMed
Cazares-Korner, C et al. (2013) CH-01 is a hypoxia-activated prodrug that sensitizes cells to hypoxia/reoxygenation through inhibition of Chk1 and Aurora A. ACS Chemical Biology 8, 1451–1459.CrossRefGoogle ScholarPubMed
Skwarska, A et al. (2021) Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor. Cell Chemical Biology 28, 1258–1270. e1213.CrossRefGoogle ScholarPubMed
Patterson, AV et al. (2007) Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clinical Cancer Research 13, 3922–3932.CrossRefGoogle ScholarPubMed
Kibuuka, P (2013) Radiotherapy + metronidazole vs radiotherapy alone in improving treatment outcomes in advanced cervical cancer in Uganda. Available at https://clinicaltrials.gov/ct2/show/NCT01937650.Google Scholar
Riaz, N et al. (2017) A personalized approach using hypoxia resolution to guide curative-intent radiation dose-reduction to 30 Gy: a novel de-escalation paradigm for HPV-associated oropharynx cancers (OPC). Journal of Clinical Oncology 35, 6076.CrossRefGoogle Scholar
Poon, I (2017) Correlation of FAZA PET hypoxia imaging to 3D histology in oral tongue cancer (FAITH). Available at https://clinicaltrials.gov/ct2/show/NCT03181035.Google Scholar
Maughan, T (2017) RHYTHM-I: investigating hypoxia in rectal tumours (RHYTHM-I). Available at https://clinicaltrials.gov/ct2/show/NCT02157246.Google Scholar
Lin, L (2013) F18 EF5 PET/CT imaging in patients with brain metastases from breast cancer. Available at https://clinicaltrials.gov/ct2/show/NCT01985971.CrossRefGoogle Scholar
Thomson, D (2013) NIMRAD (a randomised placebo-controlled trial of synchronous NIMorazole vsus RADiotherapy alone in patients with locally advanced head and neck squamous cell carcinoma not suitable for synchronous chemotherapy or cetuximab) (NIMRAD). Available at https://clinicaltrials.gov/ct2/show/NCT01950689.Google Scholar
Overgaard, J (2021) DAHANCA 30: a randomized non-inferiority trial of hypoxia-profile guided hypoxic modification of radiotherapy of HNSCC. Available at https://clinicaltrials.gov/ct2/show/NCT02661152.Google Scholar
Jens Overgaard, VG (2020) AF CRT +/– nimorazole in HNSCC. Available at https://clinicaltrials.gov/ct2/show/NCT01880359.Google Scholar
Overgaard, J (2017) DAHANCA 28A: phase I/II study on accelerated, hyperfractionated radiotherapy with concomitant cisplatin and nimorazole. Available at https://clinicaltrials.gov/ct2/show/NCT01733823.Google Scholar
Rubek, N and Buchwald, CV (2019) Quality of life after primary TORS vs IMRT for patients with early-stage oropharyngeal squamous cell carcinoma (QoLATI). Available at https://clinicaltrials.gov/ct2/show/NCT04124198.Google Scholar
Le, QT et al. (2006) Mature results from a randomized phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable stage IV head and neck squamous cell carcinomas. Cancer 106, 1940–1949.CrossRefGoogle ScholarPubMed
Le, Q-T (2014) Tirapazamine combined with chemo and RT in limited-stage small cell lung cancer, https://clinicaltrials.gov/ct2/show/NCT00066742.Google Scholar
Lau, DH (2009) Chemotherapy, tirapazamine, and radiation therapy in treating patients with non-small cell lung cancer, https://clinicaltrials.gov/ct2/show/NCT00033410.Google Scholar
Ringash, J et al. (2017) Effect of p16 status on the quality-of-life experience during chemoradiation for locally advanced oropharyngeal cancer: a substudy of randomized trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART). International Journal of Radiation Oncology Biology Physics 97, 678–686.CrossRefGoogle Scholar
DiSilvestro, PA et al. (2014) Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study. Journal of Clinical Oncology 32, 458–464.CrossRefGoogle Scholar
Rischin, D (2013) Tirapazamine, cisplatin, and radiation therapy in treating patients with stage IB, stage II, stage III, or stage IVA cervical cancer. Available at https://clinicaltrials.gov/ct2/show/NCT00098995.Google Scholar
Sanofi (2016) TRACE: tirapazamine-radiation and cisplatin evaluation. Available at https://clinicaltrials.gov/ct2/show/NCT00174837.Google Scholar
Le, QT et al. (2004) Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study. Clinical Cancer Research 10, 5418–5424.CrossRefGoogle ScholarPubMed
Novacea (2007) AQ4N in combination with radiotherapy and temozolomide in subjects with newly diagnosed glioblastoma multiforme. Available at https://clinicaltrials.gov/ct2/show/NCT00394628.Google Scholar
Hong, RL et al. (2018) Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. Annals of Oncology 29, 1972–1979.CrossRefGoogle ScholarPubMed
Japan Clinical Oncology Group (2016) Trial of pre-operative chemoradiotherapy followed by surgical resection in pancoast tumors (JCOG 9806). Available at https://clinicaltrials.gov/ct2/show/NCT00128037.Google Scholar
Harland, SJ (2013) Radiation therapy, chemotherapy, or observation in treating patients with bladder cancer. Available at https://clinicaltrials.gov/ct2/show/NCT00002490.Google Scholar
James, ND et al. (2012) Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. New England Journal of Medicine 366, 1477–1488.CrossRefGoogle ScholarPubMed
Choudhury, A et al. (2021) Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. The Lancet Oncology 22, 246–255.CrossRefGoogle ScholarPubMed
Shipley, WU (2009) Radiation therapy and chemotherapy in treating patients with stage I bladder cancer. Available at https://clinicaltrials.gov/ct2/show/NCT00981656.Google Scholar
Fischer, JJ (2013) Radiation therapy and chemotherapy in treating patients with head and neck cancer. Available at https://clinicaltrials.gov/ct2/show/NCT00002507.Google Scholar
James, RD (2013) Radiation therapy plus fluorouracil with or without additional chemotherapy in treating patients with primary anal cancer. Available at https://clinicaltrials.gov/ct2/show/NCT00025090.Google Scholar
Gunderson, LL et al. (2012) Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. Journal of Clinical Oncology 30, 4344–4351.CrossRefGoogle ScholarPubMed
Ajani, JA et al. (2008) Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. Jama 299, 1914–1921.CrossRefGoogle ScholarPubMed
Leon, O et al. (2015) Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. European Journal of Cancer 51, 2740–2746.CrossRefGoogle ScholarPubMed
Hoff, PM (2014) A study of substitution of 5-FU (fluorouracil) by capecitabine in scheme of chemo-radiotherapy in patients with squamous cell carcinoma of the anal canal. Available at https://clinicaltrials.gov/ct2/show/NCT01941966.Google Scholar
Florescu, C et al. (2021) Interim analysis of a phase II study of simultaneously integrated boost intensity modulated radiation therapy (SIB-IMRT) in combination with 5-FU and mitomycin-C among patients with locally advanced anal canal cancer. Journal of Clinical Oncology 39, e15501.CrossRefGoogle Scholar
Kachnic, LA (2013) Intensity-modulated radiation therapy, fluorouracil, and mitomycin C in treating patients with invasive anal cancer. Available at https://clinicaltrials.gov/ct2/show/NCT00423293.Google Scholar
Glassman, PM (2010) Radiation therapy plus porfiromycin in treating patients with stage III or stage IV head and neck cancer. Available at https://clinicaltrials.gov/ct2/show/NCT00003328.Google Scholar
Meng, F et al. (2012) Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Molecular Cancer Therapeutics 11, 740–751.CrossRefGoogle Scholar
Peeters, SG et al. (2015) TH-302 in combination with radiotherapy enhances the therapeutic outcome and is associated with pretreatment [18F]HX4 hypoxia PET imaging. Clinical Cancer Research 21, 2984–2992.CrossRefGoogle Scholar
Yoon, C et al. (2015) Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas. British Journal of Cancer 113, 46–56.CrossRefGoogle ScholarPubMed
Takakusagi, Y et al. (2018) Radiotherapy synergizes with the hypoxia-activated prodrug evofosfamide: in vitro and in vivo studies. Antioxidants & Redox Signaling 28, 131–140.CrossRefGoogle ScholarPubMed
Cutsem, EV et al. (2016) Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: primary analysis of the randomized, double-blind phase III MAESTRO study. Journal of Clinical Oncology 34, 193.CrossRefGoogle Scholar
Larue, RT et al. (2016) A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. BMC Cancer 16, 644.CrossRefGoogle Scholar
Zeman, EM et al. (1986) SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. International Journal of Radiation Oncology Biology Physics 12, 1239–1242.CrossRefGoogle ScholarPubMed
Cowen, RL et al. (2004) Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Research 64, 1396–1402.CrossRefGoogle ScholarPubMed
Siim, BG et al. (1997) Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Research 57, 2922–2928.Google ScholarPubMed
Rischin, D et al. (2005) Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). Journal of Clinical Oncology 23, 79–87.CrossRefGoogle Scholar
Rischin, D et al. (2010) Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. Journal of Clinical Oncology 28, 2989–2995.CrossRefGoogle ScholarPubMed
McCarthy, HO et al. (2003) Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Therapy 10, 40–48.CrossRefGoogle ScholarPubMed
Mehibel, M et al. (2016) Radiation enhances the therapeutic effect of Banoxantrone in hypoxic tumour cells with elevated levels of nitric oxide synthase. Oncology Reports 35, 1925–1932.CrossRefGoogle ScholarPubMed
Clughsey, T et al. (2007) AQ4N in combination with radiotherapy and temozolomide in subjects with newly diagnosed glioblastoma multiforme. Available at https://clinicaltrials.gov/ct2/show/NCT00394628.Google Scholar
Chen, FY-S et al. (2019) Mitomycin C modulates tumor microenvironment and enhances radiosensitivity in rectal cancer. Therapeutic Radiology and Oncology 3, 29.CrossRefGoogle Scholar
Flam, M et al. (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. Journal of Clinical Oncology 14, 2527–2539.CrossRefGoogle ScholarPubMed
Huang, R and Zhou, P-K (2020) HIF-1 signaling: a key orchestrator of cancer radioresistance. Radiation Medicine and Protection 1, 7–14.CrossRefGoogle Scholar
Schönberger, T, Fandrey, J and Prost-Fingerle, K (2021) Ways into understanding HIF inhibition. Cancers 13, 159.CrossRefGoogle ScholarPubMed
Okuno, T et al. (2018) SN-38 acts as a radiosensitizer for colorectal cancer by inhibiting the radiation-induced up-regulation of HIF-1α. Anticancer Research 38, 3323–3331.CrossRefGoogle ScholarPubMed
Zhang, Y et al. (2017) Targetable T-type calcium channels drive glioblastoma. Cancer Research 77, 3479–3490.CrossRefGoogle ScholarPubMed
Lester-Coll, NH et al. (2018) Mibefradil dihydrochoride with hypofractionated radiation for recurrent glioblastoma: a phase I dose expansion trial. Journal of Clinical Oncology 36, e14046.CrossRefGoogle Scholar
Wang, X et al. (2020) STAT3 Contributes to radioresistance in cancer. Frontiers in Oncology 10, 1120.Google ScholarPubMed
Zhang, C et al. (2014) STAT3 inhibitor NSC74859 radiosensitizes esophageal cancer via the downregulation of HIF-1α. Tumour Biology 35, 9793–9799.CrossRefGoogle ScholarPubMed
Zhang, Q et al. (2015) STAT3 inhibitor stattic enhances radiosensitivity in esophageal squamous cell carcinoma. Tumour Biology 36, 2135–2142.CrossRefGoogle ScholarPubMed
Moeller, BJ et al. (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5, 429–441.CrossRefGoogle ScholarPubMed
Oike, T et al. (2012) Suppression of HIF-1α expression and radiation resistance in acute hypoxic conditions. Experimental and Therapeutic Medicine 3, 141–145.CrossRefGoogle ScholarPubMed
Lee, DE et al. (2018) A radiosensitizing inhibitor of HIF-1 alters the optical redox state of human lung cancer cells in vitro. Scientific Reports 8, 8815.CrossRefGoogle ScholarPubMed
Palayoor, ST et al. (2008) PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. International Journal of Cancer 123, 2430–2437.CrossRefGoogle ScholarPubMed
Courtney, KD et al. (2020) HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma. Clinical Cancer Research 26, 793–803.CrossRefGoogle ScholarPubMed
Choueiri, TK et al. (2021) Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nature Medicine 27, 802–805.CrossRefGoogle ScholarPubMed
Chen, W et al. (2016) Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539, 112–117.CrossRefGoogle ScholarPubMed
Kaplan, AR and Glazer, PM (2020) Impact of hypoxia on DNA repair and genome integrity. Mutagenesis 35, 61–68.CrossRefGoogle ScholarPubMed
Brown, JS et al. (2017) Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discovery 7, 20–37.CrossRefGoogle ScholarPubMed
O'Neil, NJ, Bailey, ML and Hieter, P (2017) Synthetic lethality and cancer. Nature Reviews Genetics 18, 613–623.CrossRefGoogle ScholarPubMed
Mateo, J et al. (2019) A decade of clinical development of PARP inhibitors in perspective. Annals of Oncology 30, 1437–1447.CrossRefGoogle Scholar
Lord, CJ and Ashworth, A (2017) PARP inhibitors: synthetic lethality in the clinic. Science 355, 1152–1158.CrossRefGoogle ScholarPubMed
Chan, N et al. (2010) Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Research 70, 8045–8054.CrossRefGoogle ScholarPubMed
Begg, K and Tavassoli, M (2020) Inside the hypoxic tumour: reprogramming of the DDR and radioresistance. Cell Death Discovery 6, 77.CrossRefGoogle ScholarPubMed
Michmerhuizen, AR et al. (2019) PARP1 Inhibition radiosensitizes models of inflammatory breast cancer to ionizing radiation. Molecular Cancer Therapeutics 18, 2063–2073.CrossRefGoogle ScholarPubMed
Kirova, YM et al. (2020) Radioparp: a phase I of olaparib with radiation therapy (RT) in patients with inflammatory, locoregionally advanced or metastatic triple-negative breast cancer (TNBC) or patient with operated TNBC with residual disease – preliminary results. Journal of Clinical Oncology 38, 571.CrossRefGoogle Scholar
Lesueur, P et al. (2019) Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol. BMC Cancer 19, 198.CrossRefGoogle ScholarPubMed
de Haan, R et al. (2019) Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib. BMC Cancer 19, 901.CrossRefGoogle ScholarPubMed
Merck Sharp & Dohme Corp (2020) Study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib in stage III non-small cell lung cancer (NSCLC) (MK-7339-012/KEYLYNK-012). Available at https://clinicaltrials.gov/ct2/show/NCT04380636.Google Scholar
Forster, MD et al. (2016) ORCA-2: a phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck. Journal of Clinical Oncology 34, TPS6108.CrossRefGoogle Scholar
McKay, RR (2017) Testing the safety of different doses of olaparib given radium-223 for men with advanced prostate cancer with bone metastasis. Available at https://clinicaltrials.gov/ct2/show/NCT03317392.Google Scholar
Negrao, MV (2021) Olaparib and durvalumab with carboplatin, etoposide, and/or radiation therapy for the treatment of extensive-stage small cell lung cancer, PRIO Trial. Available at https://clinicaltrials.gov/ct2/show/NCT04728230.Google Scholar
Reiss, KA et al. (2017) A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. Gynecologic Oncology 144, 486–490.CrossRefGoogle ScholarPubMed
Chabot, P et al. (2017) Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study. Journal of Neuro-Oncology 131, 105–115.CrossRefGoogle Scholar
Kozono, DE et al. (2019) Veliparib (Vel) in combination with chemoradiotherapy (CRT) of carboplatin/paclitaxel (C/P) plus radiation in patients (pts) with stage III non-small cell lung cancer (NSCLC) (M14-360/AFT-07). Journal of Clinical Oncology 37, 8510.CrossRefGoogle Scholar
Czito, BG et al. (2017) Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study. The Lancet Gastroenterology and Hepatology 2, 418–426.CrossRefGoogle ScholarPubMed
Jelinek, MJ et al. (2018) A phase I/II trial adding poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel (Carbo-Tax) in patients with head and neck squamous cell carcinoma (HNSCC) Alliance A091101. Journal of Clinical Oncology 36, 6031.CrossRefGoogle Scholar
Mehta, MP et al. (2015) Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study. Journal of Neuro-Oncology 122, 409–417.CrossRefGoogle ScholarPubMed
Tuli, R et al. (2019) A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. EBioMedicine 40, 375–381.CrossRefGoogle ScholarPubMed
Jagsi, R et al. (2018) Concurrent veliparib with chest wall and nodal radiotherapy in patients with inflammatory or locoregionally recurrent breast cancer: the TBCRC 024 phase I multicenter study. Journal of Clinical Oncology 36, 1317–1322.CrossRefGoogle ScholarPubMed
Baxter, PA et al. (2020) A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study. Neuro-Oncology 22, 875–885.CrossRefGoogle ScholarPubMed
Argiris, A et al. (2019) S1206: a dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without veliparib in stage III non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 37, 8523.CrossRefGoogle Scholar
Spratt, D and Jackson, W (2019) A multi-center trial of androgen suppression with abiraterone acetate, leuprolide, PARP inhibition and stereotactic body radiotherapy in prostate cancer (ASCLEPIuS). Available at https://clinicaltrials.gov/ct2/show/NCT04194554.Google Scholar
Ludwig, MS (2018) Study of niraparib with radiotherapy for treatment of metastatic invasive carcinoma of the cervix (NIVIX). Available at https://clinicaltrials.gov/ct2/show/NCT03644342.Google Scholar
Ho, A (2021) Radiation, immunotherapy and PARP inhibitor in triple negative breast cancer (NADiR). Available at https://clinicaltrials.gov/ct2/show/NCT04837209.Google Scholar
Triest, BV et al. (2018) A phase Ia/Ib trial of the DNA-PK inhibitor M3814 in combination with radiotherapy (RT) in patients (pts) with advanced solid tumors: dose-escalation results. Journal of Clinical Oncology 36, 2518.CrossRefGoogle Scholar
Romesser, P et al. (2020) A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer. Journal of Clinical Oncology 38, TPS4117.CrossRefGoogle Scholar
Bendell, JC et al. (2019) Phase 1, open-label, dose-escalation study of M3814 + avelumab ± radiotherapy (RT) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology 37, TPS3169.CrossRefGoogle Scholar
Majd, N (2020) Nedisertib and radiation therapy, followed by temozolomide for the treatment of patients with newly diagnosed MGMT unmethylated glioblastoma or gliosarcoma. Available at https://clinicaltrials.gov/ct2/show/NCT04555577.Google Scholar
Gillison, ML (2020) Testing the addition of M3814 (peposertib) to radiation therapy for patients with advanced head and neck cancer who cannot take cisplatin. Available at https://clinicaltrials.gov/ct2/show/NCT04533750.Google Scholar
Reddy, VP et al. (2019) Abstract 4868: a preclinical PK/PD model based on a mouse glioblastoma survival model for AZD1390, a novel, brain-penetrant ATM kinase inhibitor, to predict the inhibition of DNA damage response induced by radiation and the human efficacious dose. Cancer Research 79, 4868.Google Scholar
Dillon, MT et al. (2018) PATRIOT: a phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours. Clinical and Translational Radiation Oncology 12, 16–20.CrossRefGoogle ScholarPubMed
Owonikoko, TK (2015) Testing the addition of M6620 (VX-970, berzosertib) to usual chemotherapy and radiation for head and neck cancer. Available at https://clinicaltrials.gov/ct2/show/NCT02567422.Google Scholar
Mohindra, P (2015) Testing the safety of M6620 (VX-970) when given with standard whole brain radiation therapy for the treatment of brain metastases from non-small cell lung cancer, small cell lung cancer, or neuroendocrine tumors. Available at https://clinicaltrials.gov/ct2/show/NCT02589522.Google Scholar
van Werkhoven, E et al. (2020) Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples. BMC Medical Research Methodology 20, 162.CrossRefGoogle ScholarPubMed
Mowery, YM (2020) Testing the addition of an anti-cancer drug, BAY1895344, with radiation therapy to the usual pembrolizumab treatment for recurrent head and neck cancer. Available at https://clinicaltrials.gov/ct2/show/NCT04576091.Google Scholar
Kong, A et al. (2020) Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol. BMJ Open 10, e033009.CrossRefGoogle Scholar
Cuneo, KC et al. (2019) Dose escalation trial of the wee1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer. Journal of Clinical Oncology 37, 2643–2650.CrossRefGoogle ScholarPubMed
Lheureux, S (2017) Testing AZD1775 in combination with radiotherapy and chemotherapy in cervical, upper vaginal and uterine cancers. Available at https://clinicaltrials.gov/ct2/show/NCT03345784.Google Scholar
Siddharth Sheth, D (2015) Dose-escalating AZD1775 + concurrent radiation + cisplatin for intermediate/high risk HNSCC. Available at https://clinicaltrials.gov/ct2/show/NCT02585973.Google Scholar
Alexander, BM et al. (2017) Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM. Journal of Clinical Oncology 35, 2005.CrossRefGoogle Scholar
Gogola, E et al. (2018) Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality. Cancer Cell 33, 1078–1093. e1012.CrossRefGoogle ScholarPubMed
Petrucelli, N, Daly, MB and Pal, T (1998) BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021.Google Scholar
Lord, CJ and Ashworth, A (2016) BRCAness revisited. Nature Reviews Cancer 16, 110–120.CrossRefGoogle ScholarPubMed
Lesueur, P et al. (2017) Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget 8, 69105–69124.CrossRefGoogle ScholarPubMed
Jiang, Y et al. (2016) Hypoxia potentiates the radiation-sensitizing effect of olaparib in human non-small cell lung cancer xenografts by contextual synthetic lethality. International Journal of Radiation Oncology Biology Physics 95, 772–781.CrossRefGoogle ScholarPubMed
Ramakrishnan Geethakumari, P et al. (2017) PARP inhibitors in prostate cancer. Current Treatment Options in Oncology 18, 37.CrossRefGoogle ScholarPubMed
Mahaney, BL, Meek, K and Lees-Miller, SP (2009) Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochemical Journal 417, 639–650.CrossRefGoogle ScholarPubMed
Goodwin, JF and Knudsen, KE (2014) Beyond DNA repair: DNA-PK function in cancer. Cancer Discovery 4, 1126–1139.CrossRefGoogle ScholarPubMed
Hsu, FM, Zhang, S and Chen, BP (2012) Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment. Translational Cancer Research 1, 22–34.Google ScholarPubMed
Geng, W et al. (2019) DNA-PKcs inhibitor increases the sensitivity of gastric cancer cells to radiotherapy. Oncology Reports 42, 561–570.Google Scholar
Jiang, Y et al. (2021) DNAPK inhibition preferentially compromises the repair of radiation-induced DNA double-strand breaks in chronically hypoxic tumor cells in xenograft models. Molecular Cancer Therapeutics 20, 1663–1671.CrossRefGoogle ScholarPubMed
Klein, C et al. (2017) Overcoming hypoxia-induced tumor radioresistance in non-small cell lung cancer by targeting DNA-dependent protein kinase in combination with carbon ion irradiation. Radiation Oncology 12, 208.CrossRefGoogle ScholarPubMed
Meschini, R et al. (2015) Role of chromatin structure modulation by the histone deacetylase inhibitor trichostatin A on the radio-sensitivity of ataxia telangiectasia. Mutation Research 777, 52–59.CrossRefGoogle ScholarPubMed
Szurman-Zubrzycka, M et al. (2019) ATR, a DNA damage signaling kinase, is involved in aluminum response in barley. Frontiers in Plant Science 10, 1299.CrossRefGoogle ScholarPubMed
Pires, IM et al. (2012) Targeting radiation-resistant hypoxic tumour cells through ATR inhibition. British Journal of Cancer 107, 291–299.CrossRefGoogle ScholarPubMed
Olcina, MM, Grand, RJ and Hammond, EM (2014) ATM activation in hypoxia – causes and consequences. Molecular & Cellular Oncology 1, e29903.CrossRefGoogle ScholarPubMed
Bencokova, Z et al. (2009) ATM activation and signaling under hypoxic conditions. Molecular and Cellular Biology 29, 526–537.CrossRefGoogle ScholarPubMed
Prevo, R et al. (2012) The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biology & Therapy 13, 1072–1081.CrossRefGoogle ScholarPubMed
Leszczynska, KB et al. (2016) Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer. Radiotherapy & Oncology 121, 232–238.CrossRefGoogle ScholarPubMed
Zeng, L et al. (2020) CHK1/2 inhibitor prexasertib suppresses NOTCH signaling and enhances cytotoxicity of cisplatin and radiation in head and neck squamous cell carcinoma. Molecular Cancer Therapeutics 19, 1279–1288.CrossRefGoogle ScholarPubMed
Zeng, L et al. (2017) Combining Chk1/2 inhibition with cetuximab and radiation enhances in vitro and in vivo cytotoxicity in head and neck squamous cell carcinoma. Molecular Cancer Therapeutics 16, 591–600.CrossRefGoogle ScholarPubMed
Li, Z et al. (2020) Development and characterization of a wee1 kinase degrader. Cell Chemical Biology 27, 57–65. e59.CrossRefGoogle ScholarPubMed
Lee, Y-Y et al. (2019) Anti-tumor effects of wee1 kinase inhibitor with radiotherapy in human cervical cancer. Scientific Reports 9, 15394.CrossRefGoogle ScholarPubMed
Cuneo, KC et al. (2016) Wee1 kinase inhibitor AZD1775 radiosensitizes hepatocellular carcinoma regardless of TP53 mutational status through induction of replication stress. International Journal of Radiation Oncology, Biology, Physics 95, 782–790.CrossRefGoogle ScholarPubMed
O'Brien, EM et al. (2013) Impact of Wee1 inhibition on the hypoxia-induced DNA damage response.CrossRefGoogle Scholar
McCann, E, O'Sullivan, J and Marcone, S (2021) Targeting cancer-cell mitochondria and metabolism to improve radiotherapy response. Translational Oncology 14, 100905.CrossRefGoogle ScholarPubMed
Zhang, Z et al. (2018) PI3K/Akt and HIF-1 signaling pathway in hypoxia-ischemia (Review). Molecular Medicine Reports 18, 3547–3554.Google Scholar
Lee, CM et al. (2006) Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clinical Cancer Research 12, 250–256.CrossRefGoogle ScholarPubMed
Chang, L et al. (2014) PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death & Disease 5, e1437.CrossRefGoogle ScholarPubMed
Fokas, E et al. (2012) Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Research 72, 239–248.CrossRefGoogle ScholarPubMed
Kelly, CJ et al. (2014) Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia. Radiotherapy & Oncology 111, 72–80.CrossRefGoogle ScholarPubMed
Sastri, SJ and Goda, J (2020) Radiosensitizing effect of nelfinavir in locally advanced carcinoma of cervix (NELCER). Available at https://clinicaltrials.gov/ct2/show/NCT03256916.Google Scholar
Rengan, R et al. (2012) A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response. Journal of Thoracic Oncology 7, 709–715.CrossRefGoogle Scholar
Yang, TJ (2019) GDC-0084 with radiation therapy for people with PIK3CA-mutated solid tumor brain metastases or leptomeningeal metastases. Available at https://clinicaltrials.gov/ct2/show/NCT04192981.Google Scholar
Tinkle, C and Gajjar, A (2018) Study of GDC-0084 in pediatric patients with newly diagnosed diffuse intrinsic pontine glioma or diffuse midline gliomas. Available at https://clinicaltrials.gov/ct2/show/NCT03696355.Google Scholar
Mueller, S (2021) Combination therapy for the treatment of diffuse midline gliomas. Available at https://clinicaltrials.gov/ct2/show/NCT05009992.Google Scholar
Glorieux, M, Dok, R and Nuyts, S (2020) The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells. Scientific Reports 10, 16208.CrossRefGoogle ScholarPubMed
Brunner, TB et al. (2008) Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. Journal of Clinical Oncology 26, 2699–2706.CrossRefGoogle ScholarPubMed
Buijsen, J et al. (2013) Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer. Radiotherapy and Oncology 107, 184–188.CrossRefGoogle ScholarPubMed
Garcia-Soto, AE et al. (2015) Phase I trial of nelfinavir added to cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer. Journal of Clinical Oncology 33, TPS5619.CrossRefGoogle Scholar
Baumert, B (2015) Study with nelfinavir and combined radiochemotherapy for glioblastoma. Available at https://clinicaltrials.gov/ct2/show/NCT00694837.Google Scholar
Tran, P (2021) Stereotactic body radiation with nelfinavir for oligometastases. Available at https://clinicaltrials.gov/ct2/show/NCT01728779.Google Scholar
Lin, C et al. (2019) Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma. Radiotherapy & Oncology 132, 55–62.CrossRefGoogle ScholarPubMed
Hansen, A (2015) Phase I study of BYL719 in combination with cisplatin and radiotherapy in patients with squamous cell head and neck cancer. Available at https://clinicaltrials.gov/ct2/show/NCT02537223.Google Scholar
Operations, CS (2013) A study of XL765 (SAR245409) in combination with temozolomide with and without radiation in adults with malignant gliomas. Available at https://clinicaltrials.gov/ct2/show/NCT00704080.Google Scholar
Graillon, T and Arnaud, J-O (2018) Combination of alpelisib and trametinib in progressive refractory meningiomas (ALTREM). Available at https://clinicaltrials.gov/ct2/show/NCT03631953.Google Scholar
Pharmaceuticals, N (2010) A study of mTOR inhibitor everolimus (RAD001) in association with cisplatin and radiotherapy for locally advanced cervix cancer (PHOENIX I). Available at https://clinicaltrials.gov/ct2/show/NCT01217177.Google Scholar
Narayan, V et al. (2016) Phase I trial of everolimus plus radiation therapy for salvage treatment of biochemical recurrence in prostate cancer patients following prostatectomy. Journal of Clinical Oncology 34, e16617.CrossRefGoogle Scholar
Buijsen, J (2019) Safety study of rapamycin administered before and during radiotherapy to treat rectum cancer. Available at https://clinicaltrials.gov/ct2/show/NCT00409994.Google Scholar
Williams, KJ et al. (2005) Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiotherapy & Oncology 75, 89–98.CrossRefGoogle ScholarPubMed
Hudes, G et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine 356, 2271–2281.CrossRefGoogle ScholarPubMed
Kido, T et al. (2020) Glucose transporter 1 is important for the glycolytic metabolism of human endometrial stromal cells in hypoxic environment. Heliyon 6, e03985.CrossRefGoogle ScholarPubMed
Boström, PJ et al. (2016) Hypoxia marker GLUT-1 (glucose transporter 1) is an independent prognostic factor for survival in bladder cancer patients treated with radical cystectomy. Bladder Cancer 2, 101–109.CrossRefGoogle ScholarPubMed
Tang, L et al. (2018) Role of metabolism in cancer cell radioresistance and radiosensitization methods. Journal of Experimental & Clinical Cancer Research 37, 87.CrossRefGoogle ScholarPubMed
Kunkel, M et al. (2007) Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity. Oral Oncology 43, 796–803.CrossRefGoogle ScholarPubMed
Zhao, F et al. (2016) Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation. Cancer Chemotherapy and Pharmacology 77, 963–972.CrossRefGoogle ScholarPubMed
Shen, H et al. (2015) Sensitization of glioblastoma cells to irradiation by modulating the glucose metabolism. Molecular Cancer Therapeutics 14, 1794–1804.CrossRefGoogle ScholarPubMed
Storozynsky, Q and Hitt, MM (2020) The impact of radiation-induced DNA damage on cGAS-STING-mediated immune responses to cancer. International Journal of Molecular Sciences 21, 8877.CrossRefGoogle ScholarPubMed
Deng, J et al. (2019) Hypoxia-Induced VISTA promotes the suppressive function of myeloid-derived suppressor cells in the tumor microenvironment. Cancer Immunology Research 7, 1079–1090.CrossRefGoogle ScholarPubMed
Boutilier, AJ and Elsawa, SF (2021) Macrophage polarization states in the tumor microenvironment. International Journal of Molecular Sciences 22, 6995.CrossRefGoogle ScholarPubMed
Winning, S and Fandrey, J (2016) Dendritic cells under hypoxia: how oxygen shortage affects the linkage between innate and adaptive immunity. Journal of Immunology Research 2016, 5134329.CrossRefGoogle ScholarPubMed
Kumar, V and Gabrilovich, DI (2014) Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology 143, 512–519.CrossRefGoogle ScholarPubMed
Vanpouille-Box, C, Formenti, SC and Demaria, S (2018) Toward precision radiotherapy for use with immune checkpoint blockers. Clinical Cancer Research 24, 259–265.CrossRefGoogle ScholarPubMed
Pilones, KA, Vanpouille-Box, C and Demaria, S (2015) Combination of radiotherapy and immune checkpoint inhibitors. Seminars in Radiation Oncology 25, 28–33.CrossRefGoogle ScholarPubMed
Jing, Z et al. (2018) Combination of radiation therapy and anti-PD-1 antibody SHR-1210 in treating patients with esophageal squamous cell cancer. International Journal of Radiation Oncology, Biology, Physics 102, e31.CrossRefGoogle Scholar
Pang, Q et al. (2018) Safety and effect of radiation therapy combined with anti-PD-1 antibody SHR-1210 as first-line treatment on patients with intolerable concurrent chemoradiotherapy esophageal cancer: a phase 1B clinical trial. International Journal of Radiation Oncology, Biology, Physics 102, e39.CrossRefGoogle Scholar
Shaverdian, N et al. (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. The Lancet. Oncology 18, 895–903.CrossRefGoogle ScholarPubMed
Kim, C et al. (2020) Phase I study of the (177)Lu-DOTA(0)-Tyr(3)-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. Journal for Immunotherapy of Cancer 8, e000980.CrossRefGoogle Scholar
El-Khoueiry, AB et al. (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389, 2492–2502.CrossRefGoogle ScholarPubMed
Bozorgmehr, F et al. (2019) Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer – study protocol of the FORCE trial. BMC Cancer 19, 1074.CrossRefGoogle ScholarPubMed
Pryor, D et al. (2021) A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): clinical trial protocol. Contemporary Clinical Trials Communications 21, 100703.CrossRefGoogle ScholarPubMed
Takiar, V and Corp, MSD (2021) A study of chemoradiation plus pembrolizumab for locally advanced laryngeal squamous cell carcinoma. Available at https://clinicaltrials.gov/ct2/show/NCT02759575.Google Scholar
Kolstad, A (2021) Sequential intranodal immunotherapy (SIIT) combined with anti-PD1 (pembrolizumab) in follicular lymphoma (Lymvac-2). Available at https://clinicaltrials.gov/ct2/show/NCT02677155.Google Scholar
Maity, A et al. (2018) A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. British Journal of Cancer 119, 1200–1207.CrossRefGoogle ScholarPubMed
Loi, S and David, S (2017) Pilot study of stereotactic ablation for oligometastatic breast neoplasia in combination with the anti-PD-1 antibody MK-3475 (BOSTON II). Available at https://clinicaltrials.gov/ct2/show/NCT02303366.Google Scholar
Park, H et al. (2019) Abstract CT212: combining pembrolizumab with locally delivered radiation therapy for the treatment of metastatic esophageal cancer. Cancer Research 79, CT212.Google Scholar
Bjarnason, G (2021) A proof of principle study of pembrolizumab with SBRT in TKI mRCC patients (OZM-065). Available at https://clinicaltrials.gov/ct2/show/NCT02599779.Google Scholar
Monjazeb, A (2020) UCDCC#269: a pilot study of interlesional IL-2 and RT in patients with NSCLC. Available at https://clinicaltrials.gov/ct2/show/NCT03224871.Google Scholar
Floudas, CS et al. (2019) A pilot study of the PD-1 targeting agent AMP-224 used with low-dose cyclophosphamide and stereotactic body radiation therapy in patients with metastatic colorectal cancer. Clinical Colorectal Cancer 18, e349–e360.CrossRefGoogle ScholarPubMed
Daly, M (2021) Avelumab and stereotactic ablative radiotherapy in non-responding and progressing NSCLC patients. Available at https://clinicaltrials.gov/ct2/show/NCT03158883.Google Scholar
Kurz, S (2021) Avelumab with hypofractionated radiation therapy in adults with isocitrate dehydrogenase (IDH) mutant glioblastoma. Available at https://clinicaltrials.gov/ct2/show/NCT02968940.Google Scholar
Babiker, H et al. (2021) Phase I trial of cemiplimab, radiotherapy, cyclophosphamide, and granulocyte macrophage colony-stimulating factor in patients with recurrent or metastatic head and neck squamous cell carcinoma. The Oncologist 26, e1508–e1513.CrossRefGoogle ScholarPubMed
Rischin, D et al. (2020) Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. Journal for Immunotherapy of Cancer 8, e000775.CrossRefGoogle ScholarPubMed
Chachoua, A (2020) Study of combined ionizing radiation and ipilimumab in metastatic non-small cell lung cancer (NSCLC). Available at https://clinicaltrials.gov/ct2/show/NCT02221739.Google Scholar
Cheson, BD et al. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology 17, 1244.CrossRefGoogle ScholarPubMed
Hiniker, SM et al. (2016) A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma. International Journal of Radiation Oncology Biology Physics 96, 578–588.CrossRefGoogle ScholarPubMed
Ost, P (2017) Trial of SBRT with concurrent ipilimumab in metastatic melanoma. Available at https://clinicaltrials.gov/ct2/show/NCT02406183.Google Scholar
López-Martín, JA (2021) GEM STUDY: radiation and Yervoy in patients with melanoma and brain metastases (GRAY-B). Available at https://clinicaltrials.gov/ct2/show/NCT02115139.Google Scholar
Da Silva, DM et al. (2020) Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929). Clinical Cancer Research 26, 5621–5630.CrossRefGoogle Scholar
Reyes-Gibby, CC et al. (2007) Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. Journal of Pain and Symptom Management 34, 244–252.CrossRefGoogle ScholarPubMed
Pakkala, S et al. (2020) Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study. Journal for Immunotherapy of Cancer 8, e001302.CrossRefGoogle ScholarPubMed
Jones, KI et al. (2018) Radiation combined with macrophage depletion promotes adaptive immunity and potentiates checkpoint blockade. EMBO Molecular Medicine 10, e9342.CrossRefGoogle ScholarPubMed
Eckert, F et al. (2019) Rationale for combining radiotherapy and immune checkpoint inhibition for patients with hypoxic tumors. Frontiers in Immunology 10, 407.CrossRefGoogle ScholarPubMed
Cho, B (2018) Intensity-modulated radiation therapy: a review with a physics perspective. Radiation Oncology Journal 36, 1–10.CrossRefGoogle ScholarPubMed
Marta, GN et al. (2014) Intensity-modulated radiation therapy for head and neck cancer: systematic review and meta-analysis. Radiotherapy & Oncology 110, 9–15.CrossRefGoogle ScholarPubMed
Wang, H et al. (2018) Cancer radiosensitizers. Trends in Pharmacological Sciences 39, 24–48.CrossRefGoogle ScholarPubMed
Kim, MS et al. (2016) Gold nanoparticles enhance anti-tumor effect of radiotherapy to hypoxic tumor. Radiation Oncology Journal 34, 230–238.CrossRefGoogle ScholarPubMed
Huefner, ND et al. (2014) Genomic stability in response to high versus low linear energy transfer radiation in Arabidopsis thaliana. Frontiers in Plant Science 5, 206.CrossRefGoogle ScholarPubMed
Ilicic, K, Combs, SE and Schmid, TE (2018) New insights in the relative radiobiological effectiveness of proton irradiation. Radiation Oncology 13, 6.CrossRefGoogle ScholarPubMed
Costes, SV et al. (2007) Image-based modeling reveals dynamic redistribution of DNA damage into nuclear sub-domains. PLoS Computational Biology 3, e155.CrossRefGoogle ScholarPubMed
Wenzl, T and Wilkens, JJ (2011) Modelling of the oxygen enhancement ratio for ion beam radiation therapy. Physics in Medicine and Biology 56, 3251–3268.CrossRefGoogle ScholarPubMed
Nikjoo, H et al. (2001) Computational approach for determining the spectrum of DNA damage induced by ionizing radiation. Radiation Research 156, 577–583. 577.CrossRefGoogle ScholarPubMed
Roobol, SJ et al. (2020) Comparison of high- and low-LET radiation-induced DNA double-strand break processing in living cells. International Journal of Molecular Sciences 21, 6602.CrossRefGoogle ScholarPubMed
Cao, W et al. (2017) Linear energy transfer incorporated intensity modulated proton therapy optimization. Physics in Medicine and Biology 63, 015013.CrossRefGoogle ScholarPubMed
Le Caër, S (2011) Water radiolysis: influence of oxide surfaces on H2 production under ionizing radiation. Water 3, 2073–4441.CrossRefGoogle Scholar
Desouky, O, Ding, N and Zhou, G (2015) Targeted and non-targeted effects of ionizing radiation. Journal of Radiation Research and Applied Sciences 8, 247–254.CrossRefGoogle Scholar
Wilson, JD et al. (2019) Ultra-high dose rate (FLASH) radiotherapy: silver bullet or fool's gold? Frontiers in Oncology 9, 1563.CrossRefGoogle ScholarPubMed
Diffenderfer, ES et al. (2020) Design, implementation, and in vivo validation of a novel proton FLASH radiation therapy system. International Journal of Radiation Oncology Biology Physics 106, 440–448.CrossRefGoogle ScholarPubMed
Moon, EJ, Petersson, K and Olcina, MM (2022) The importance of hypoxia in radiotherapy for the immune response, metastatic potential and FLASH-RT. International Journal of Radiation Biology 98, 439–451.CrossRefGoogle ScholarPubMed
Fouillade, C et al. (2020) FLASH irradiation spares lung progenitor cells and limits the incidence of radio-induced senescence. Clinical Cancer Research 26, 1497–1506.CrossRefGoogle ScholarPubMed
Hughes, JR and Parsons, JL (2020) FLASH radiotherapy: current knowledge and future insights using proton-beam therapy. International Journal of Molecular Sciences 21, 6492.CrossRefGoogle ScholarPubMed
Adrian, G et al. (2020) The FLASH effect depends on oxygen concentration. The British Journal of Radiology 93, 20190702.CrossRefGoogle ScholarPubMed
Busk, M, Horsman, MR and Overgaard, J (2008) Resolution in PET hypoxia imaging: voxel size matters. Acta Oncologica 47, 1201–1210.CrossRefGoogle ScholarPubMed
van der Heide, UA et al. (2012) Functional MRI for radiotherapy dose painting. Magnetic Resonance Imaging 30, 1216–1223.CrossRefGoogle ScholarPubMed
Donche, S et al. (2019) The path toward PET-guided radiation therapy for glioblastoma in laboratory animals: a mini review. Frontiers in Medicine 6, 5.CrossRefGoogle ScholarPubMed